X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs STERLING BIOTECH - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD STERLING BIOTECH ORCHID PHARMA LTD/
STERLING BIOTECH
 
P/E (TTM) x -0.1 -0.4 - View Chart
P/BV x 0.1 0.0 779.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   STERLING BIOTECH
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
STERLING BIOTECH
Dec-13
ORCHID PHARMA LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs19411 1,847.6%   
Low Rs353 1,029.4%   
Sales per share (Unadj.) Rs276.526.8 1,031.3%  
Earnings per share (Unadj.) Rs-79.2-15.0 529.6%  
Cash flow per share (Unadj.) Rs-43.5-5.5 795.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.954.9 98.3%  
Shares outstanding (eoy) m70.45267.87 26.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.40.3 159.7%   
Avg P/E ratio x-1.4-0.5 311.1%  
P/CF ratio (eoy) x-2.6-1.3 207.1%  
Price / Book Value ratio x2.10.1 1,676.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,0671,862 433.3%   
No. of employees `0002.81.4 206.8%   
Total wages/salary Rs m2,527547 462.1%   
Avg. sales/employee Rs Th6,956.15,303.3 131.2%   
Avg. wages/employee Rs Th902.5403.8 223.5%   
Avg. net profit/employee Rs Th-1,993.0-2,959.0 67.4%   
INCOME DATA
Net Sales Rs m19,4777,181 271.2%  
Other income Rs m40743 955.9%   
Total revenues Rs m19,8847,223 275.3%   
Gross profit Rs m1,103947 116.4%  
Depreciation Rs m2,5192,543 99.1%   
Interest Rs m5,2274,377 119.4%   
Profit before tax Rs m-6,236-5,931 105.1%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125-1,924 6.5%   
Profit after tax Rs m-5,580-4,007 139.3%  
Gross profit margin %5.713.2 42.9%  
Effective tax rate %2.032.4 6.2%   
Net profit margin %-28.7-55.8 51.3%  
BALANCE SHEET DATA
Current assets Rs m11,01414,335 76.8%   
Current liabilities Rs m32,06049,809 64.4%   
Net working cap to sales %-108.1-494.0 21.9%  
Current ratio x0.30.3 119.4%  
Inventory Days Days95403 23.5%  
Debtors Days Days34171 19.7%  
Net fixed assets Rs m29,44055,432 53.1%   
Share capital Rs m705268 263.0%   
"Free" reserves Rs m2,04313,935 14.7%   
Net worth Rs m3,80014,701 25.8%   
Long term debt Rs m9,0189,478 95.1%   
Total assets Rs m46,51073,988 62.9%  
Interest coverage x-0.2-0.4 54.4%   
Debt to equity ratio x2.40.6 368.1%  
Sales to assets ratio x0.40.1 431.5%   
Return on assets %-0.80.5 -151.7%  
Return on equity %-146.9-27.3 538.9%  
Return on capital %-3.7-6.4 58.1%  
Exports to sales %37.925.9 146.2%   
Imports to sales %22.60.2 13,314.9%   
Exports (fob) Rs m7,3781,860 396.7%   
Imports (cif) Rs m4,40612 36,115.6%   
Fx inflow Rs m7,5131,860 404.0%   
Fx outflow Rs m5,64925 22,695.1%   
Net fx Rs m1,8651,835 101.6%   
CASH FLOW
From Operations Rs m1,6821,719 97.8%  
From Investments Rs m-9,860-3,148 313.2%  
From Financial Activity Rs m6,6441,426 465.9%  
Net Cashflow Rs m-1,535-3 45,147.1%  

Share Holding

Indian Promoters % 32.3 33.9 95.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 0.0 -  
FIIs % 3.3 9.9 33.3%  
ADR/GDR % 4.6 16.9 27.2%  
Free float % 55.3 39.3 140.7%  
Shareholders   84,811 21,482 394.8%  
Pledged promoter(s) holding % 54.9 55.9 98.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CIPLA  SANOFI INDIA  ALKEM LABORATORIES  ALEMBIC PHARMA  DIVIS LABORATORIES  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Dec 14, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - WOCKHARDT LTD. COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS